Pfizer Reports Second Phase III Failure in a Week: Torisel, Bevacizumab Combo for Advanced RCC

In the second late-stage failure for Pfizer this week, the company saw disappointing results for its Torisel when combined with Roche’s Avastin as a first-line treatment for advanced renal cell carcinoma (RCC). The trial, which pitted the combo against Avastin (bevacizumab) plus interferon-alfa-2a (IFN-α-2a), did not show superiority in extending progression free survival (PFS). Pfizer is analyzing additional efficacy endpoints and safety data, it said.
Drug Industry Daily